Depressed levels of prostaglandin F2α in mice lacking Akr1b7 increase basal adiposity and predispose to diet-induced obesity

Diabetes

Volumn 61, Issue 11, 2012, Pages 2796-2806

  Volat, Fanny E ^a   Pointud, Jean Christophe ^a   Pastel, Emilie ^a   Morio, Béatrice ^b   Sion, Benoit ^a   Hamard, Ghislaine ^c   Guichardant, Michel ^d   Colas, Romain ^d   Lefrançois Martinez, Anne Marie ^a   Martinez, Antoine ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b INRA and University of Auvergne   (France)

^c INSTITUT COCHIN   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AKR1B7 PROTEIN; CLOPROSTENOL; OXIDOREDUCTASE; PROSTAGLANDIN F2 ALPHA; UNCLASSIFIED DRUG;

ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL HYPERPLASIA; CELL SIZE; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; FATTY LIVER; FEMALE; HOMEOSTASIS; INSULIN RESISTANCE; LIPOGENESIS; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN DEPLETION; TISSUE EXPANSION; WHITE ADIPOSE TISSUE;

3T3-L1 CELLS; ADIPOGENESIS; ADIPOSE TISSUE, WHITE; ADIPOSITY; ALDEHYDE REDUCTASE; ANIMALS; ANTI-OBESITY AGENTS; CELL SIZE; CLOPROSTENOL; CROSSES, GENETIC; DIET, HIGH-FAT; DINOPROST; DISEASE SUSCEPTIBILITY; DOWN-REGULATION; INSULIN RESISTANCE; LIPOGENESIS; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; OBESITY;

EID: 84868025667     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1297     Document Type: Article

References (47)

1. Haslam DW, James WP. Obesity. Lancet 2005;366:1197-1209
2. Knittle JL, Timmers K, Ginsberg-Fellner F, Brown RE, Katz DP. The growth of adipose tissue in children and adolescents. Cross-sectional and longitudinal studies of adipose cell number and size. J Clin Invest 1979;63:239-246
3. Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in humans. Nature 2008;453:783-787
4. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-2556
5. Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 2006;7:885-896
6. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006;444:847-853
7. Otto TC, Lane MD. Adipose development: from stem cell to adipocyte. Crit Rev Biochem Mol Biol 2005;40:229-242
8. Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 2000;16:145-171
9. Fujitani Y, Aritake K, Kanaoka Y, et al. Pronounced adipogenesis and increased insulin sensitivity caused by overproduction of prostaglandin D2 in vivo. FEBS J 2010;277:1410-1419
10. Ghoshal S, Trivedi DB, Graf GA, Loftin CD. Cyclooxygenase-2 deficiency attenuates adipose tissue differentiation and inflammation in mice. J Biol Chem 2011;286:889-898
11. Jaworski K, Ahmadian M, Duncan RE, et al. AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency. Nat Med 2009;15:159-168
12. Casimir DA, Miller CW, Ntambi JM. Preadipocyte differentiation blocked by prostaglandin stimulation of prostanoid FP2 receptor in murine 3T3-L1 cells. Differentiation 1996;60:203-210
13. Serrero G, Lepak NM. Prostaglandin F2alpha receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. Biochem Biophys Res Commun 1997;233:200-202
14. Fujimori K, Ueno T, Amano F. Prostaglandin F(2alpha) suppresses early phase of adipogenesis, but is not associated with osteoblastogenesis in mouse mesenchymal stem cells. Prostaglandins Other Lipid Mediat 2010;93: 52-59
15. Liu L, Clipstone NA. Prostaglandin F2alpha inhibits adipocyte differentiation via a G alpha q-calcium-calcineurin-dependent signaling pathway. J Cell Biochem 2007;100:161-173
16. Liu L, Clipstone NA. Prostaglandin F2alpha induces the normoxic activation of the hypoxia-inducible factor-1 transcription factor in differentiating 3T3-L1 preadipocytes: Potential role in the regulation of adipogenesis. J Cell Biochem 2008;105:89-98
17. Kabututu Z, Manin M, Pointud J-C, et al. Prostaglandin F2alpha synthase activities of aldo-keto reductase 1B1, 1B3 and 1B7. J Biochem 2009;145:161-168
18. Fujimori K, Ueno T, Nagata N, et al. Suppression of adipocyte differentiation by aldo-keto reductase 1B3 acting as prostaglandin F2alpha synthase. J Biol Chem 2010;285:8880-8886
19. Baba SP, Hellmann J, Srivastava S, Bhatnagar A. Aldose reductase (AKR1B3) regulates the accumulation of advanced glycosylation end products (AGEs) and the expression of AGE receptor (RAGE). Chem Biol Interact 2011;191:357-363
20. Brockstedt E, Peters-Kottig M, Badock V, Hegele-Hartung C, Lessl M. Luteinizing hormone induces mouse vas deferens protein expression in the murine ovary. Endocrinology 2000;141:2574-2581
21. Lau ET, Cao D, Lin C, Chung SK, Chung SS. Tissue-specific expression of two aldose reductase-like genes in mice: abundant expression of mouse vas deferens protein and fibroblast growth factor-regulated protein in the adrenal gland. Biochem J 1995;312:609-615
22. Martinez A, Aigueperse C, Val P, et al. Physiological functions and hormonal regulation of mouse vas deferens protein (AKR1B7) in steroidogenic tissues. Chem Biol Interact 2001;130-132:903-917
23. Volle DH, Repa JJ, Mazur A, et al. Regulation of the aldo-keto reductase gene akr1b7 by the nuclear oxysterol receptor LXRalpha (liver X receptor-alpha) in the mouse intestine: putative role of LXRs in lipid detoxification processes. Mol Endocrinol 2004;18:888-898
24. Tirard J, Gout J, Lefrançois-Martinez AM, Martinez A, Begeot M, Naville D. A novel inhibitory protein in adipose tissue, the aldo-keto reductase AKR1B7: its role in adipogenesis. Endocrinology 2007;148:1996-2005
25. Lambert-Langlais S, Pointud J-C, Lefrançois-Martinez A-M, et al. Aldo keto reductase 1B7 and prostaglandin F2alpha are regulators of adrenal endocrine functions. PLoS ONE 2009;4:e7309
26. Leneuve P, Colnot S, Hamard G, et al. Cre-mediated germline mosaicism: a new transgenic mouse for the selective removal of residual markers from tri-lox conditional alleles. Nucleic Acids Res 2003;31:e21
27. Baumann C, Davies B, Peters M, Kaufmann-Reiche U, Lessl M, Theuring F. AKR1B7 (mouse vas deferens protein) is dispensable for mouse development and reproductive success. Reproduction 2007;134:97-109
28. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 1949;109:1-9
29. Grizard G, Sion B, Bauchart D, Boucher D. Separation and quantification of cholesterol and major phospholipid classes in human semen by highperformance liquid chromatography and light-scattering detection. J Chromatogr B Biomed Sci Appl 2000;740:101-107
30. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166-2170
31. Liu MJ, Takahashi Y, Wada T, et al. The aldo-keto reductase Akr1b7 gene is a common transcriptional target of xenobiotic receptors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol 2009;76:604-611
32. Schmidt DR, Schmidt S, Holmstrom SR, et al. AKR1B7 is induced by the farnesoid X receptor and metabolizes bile acids. J Biol Chem 2011;286: 2425-2432
33. Kotokorpi P, Gardmo C, Nyström CS, Mode A. Activation of the glucocorticoid receptor or liver X receptors interferes with growth hormone-induced akr1b7 gene expression in rat hepatocytes. Endocrinology 2004;145:5704-5713
34. Jia G, Takahashi R, Zhang Z, Tsuji Y, Sone H. Aldo-keto reductase 1 family B7 is the gene induced in response to oxidative stress in the livers of LongEvans Cinnamon rats. Int J Oncol 2006;29:829-838
35. Ge X, Yin L, Ma H, Li T, Chiang JY, Zhang Y. Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasis. J Lipid Res 2011;52:1561-1568
36. Lefrançois-Martinez A-M, Bertherat J, Val P, et al. Decreased expression of cyclic adenosine monophosphate-regulated aldose reductase (AKR1B1) is associated with malignancy in human sporadic adrenocortical tumors. J Clin Endocrinol Metab 2004;89:3010-3019
37. Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 2007;21:1443-1455
38. Lefrançois-Martinez AM, Tournaire C, Martinez A, et al. Product of side-chain cleavage of cholesterol, isocaproaldehyde, is an endogenous specific substrate of mouse vas deferens protein, an aldose reductase-like protein in adrenocortical cells. J Biol Chem 1999;274:32875-32880
39. Singh SP, Niemczyk M, Saini D, Awasthi YC, Zimniak L, Zimniak P. Role of the electrophilic lipid peroxidation product 4-hydroxynonenal in the development and maintenance of obesity in mice. Biochemistry 2008;47:3900-3911
40. Grimsrud PA, Picklo MJ Sr, Griffin TJ, Bernlohr DA. Carbonylation of adipose proteins in obesity and insulin resistance: identification of adipocyte fatty acid-binding protein as a cellular target of 4-hydroxynonenal. Mol Cell Proteomics 2007;6:624-637
41. Soares AF, Guichardant M, Cozzone D, et al. Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radic Biol Med 2005;38:882-889
42. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-1761
43. Sekiya M, Yahagi N, Matsuzaka T, et al. SREBP-1-independent regulation of lipogenic gene expression in adipocytes. J Lipid Res 2007;48:1581-1591
44. Quinkler M, Bujalska IJ, Tomlinson JW, Smith DM, Stewart PM. Depotspecific prostaglandin synthesis in human adipose tissue: a novel possible mechanism of adipogenesis. Gene 2006;380:137-143
45. Suzuki-Yamamoto T, Nishizawa M, Fukui M, et al. cDNA cloning, expression and characterization of human prostaglandin F synthase. FEBS Lett 1999;462:335-340
46. Bresson E, Boucher-Kovalik S, Chapdelaine P, et al. The human aldose reductase AKR1B1 qualifies as the primary prostaglandin F synthase in the endometrium. J Clin Endocrinol Metab 2011;96:210-219
47. Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 2005;26:380-392